These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35062716)

  • 41. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.
    Bossa F; Carparelli S; Latiano A; Palmieri O; Tavano F; Panza A; Pastore M; Marseglia A; D'Altilia M; Latiano T; Corritore G; Martino G; Nardella M; Guerra M; Terracciano F; Sacco M; Perri F; Andriulli A
    Dig Liver Dis; 2021 Mar; 53(3):277-282. PubMed ID: 33423942
    [TBL] [Abstract][Full Text] [Related]  

  • 42. P044 A Profile of New Start IBD Patients on Multiple Advanced/Biologic Therapies.
    John E
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S11. PubMed ID: 37461962
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
    Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of tumor necrosis factor antagonist combination and anti-integrin therapies on body mass index in inflammatory bowel disease: A cross-sectional study.
    Shehab M; Alali A; Al-Hindawi A; Alsayegh A; Aldallal U; Abdullah I; Albaghli A; Alrashed F; Alfadhli A; Bessissow T
    Front Med (Lausanne); 2022; 9():1045661. PubMed ID: 36687448
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.
    Dolinger MT; Spencer EA; Lai J; Dunkin D; Dubinsky MC
    Inflamm Bowel Dis; 2021 Jul; 27(8):1210-1214. PubMed ID: 33125058
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project.
    Davis RL; Kramarz P; Bohlke K; Benson P; Thompson RS; Mullooly J; Black S; Shinefield H; Lewis E; Ward J; Marcy SM; Eriksen E; Destefano F; Chen R;
    Arch Pediatr Adolesc Med; 2001 Mar; 155(3):354-9. PubMed ID: 11231801
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-world biologic treatment and associated cost in patients with inflammatory bowel disease.
    Brandes A; Groth A; Gottschalk F; Wilke T; Ratsch BA; Orzechowski HD; Fuchs A; Deiters B; Bokemeyer B
    Z Gastroenterol; 2019 Jul; 57(7):843-851. PubMed ID: 31288280
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adverse Events and Compliance Among Inflammatory Bowel Disease Patients Treated With Home- vs Office-Based Biologic Infusions.
    Schmoyer CJ; Sun K; Zack J; Kumar P; Shivashankar R
    Inflamm Bowel Dis; 2024 Sep; 30(9):1529-1535. PubMed ID: 37819840
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SARS-CoV-2-inactivated vaccine hesitancy and the safety in inflammatory bowel disease patients: a single-center study.
    Cao Y; Feng J; Duan S; Yang Y; Zhang Y
    Therap Adv Gastroenterol; 2022; 15():17562848221101722. PubMed ID: 35706827
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dual Biologic or Small Molecule Therapy in Refractory Pediatric Inflammatory Bowel Disease (DOUBLE-PIBD): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN.
    Yerushalmy-Feler A; Olbjorn C; Kolho KL; Aloi M; Musto F; Martin-de-Carpi J; Lozano-Ruf A; Yogev D; Matar M; Scarallo L; Bramuzzo M; de Ridder L; Kang B; Norden C; Wilson DC; Tzivinikos C; Turner D; Cohen S
    Inflamm Bowel Dis; 2024 Feb; 30(2):159-166. PubMed ID: 37042978
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antibody Responses to SARS-CoV-2 After Infection or Vaccination in Children and Young Adults With Inflammatory Bowel Disease.
    Dailey J; Kozhaya L; Dogan M; Hopkins D; Lapin B; Herbst K; Brimacombe M; Grandonico K; Karabacak F; Schreiber J; Liang BT; Salazar JC; Unutmaz D; Hyams JS
    Inflamm Bowel Dis; 2022 Jul; 28(7):1019-1026. PubMed ID: 34528661
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD.
    Card TR; Nakafero G; Grainge MJ; Mallen CD; Van-Tam JSN; Williams HC; Abhishek A
    Am J Gastroenterol; 2023 Aug; 118(8):1388-1394. PubMed ID: 36826512
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biologics in inflammatory bowel disease: what are the data?
    Côté-Daigneault J; Bouin M; Lahaie R; Colombel JF; Poitras P
    United European Gastroenterol J; 2015 Oct; 3(5):419-28. PubMed ID: 26535119
    [TBL] [Abstract][Full Text] [Related]  

  • 55. P034 State of Health Maintenance Among IBD Patients at a Tertiary Care Center in Abu Dhabi, United Arab Emirates.
    Aldhaleei W; Almessabi A; Wallace M; Malik T
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S8-S9. PubMed ID: 37461953
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry.
    Zacharopoulou E; Orfanoudaki E; Tzouvala M; Tribonias G; Kokkotis G; Kitsou V; Almpani F; Christidou A; Viazis N; Mantzaris GJ; Tsafaridou M; Karmiris K; Theodoropoulou A; Papathanasiou E; Zampeli E; Michopoulos S; Tigkas S; Michalopoulos G; Laoudi E; Karatzas P; Mylonas I; Kyriakos N; Liatsos C; Kafetzi T; Theocharis G; Taka S; Panagiotopoulou K; Koutroubakis IE; Bamias G
    Inflamm Bowel Dis; 2023 Feb; 29(2):228-237. PubMed ID: 35394529
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vedolizumab Is Safe and Efficacious for the Treatment of Pediatric-Onset Inflammatory Bowel Disease Patients Who Fail a Primary Biologic Agent.
    Choi S; Kim ES; Kwon Y; Kim MJ; Choe YH; Choe BH; Kang B
    J Korean Med Sci; 2022 Sep; 37(37):e282. PubMed ID: 36163478
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.
    AlRuthia Y; Almadi M; Aljebreen A; Azzam N; Alsharif W; Alrasheed H; Almuaythir G; Saeed M; HajkhderMullaissa B; Alharbi O
    J Med Econ; 2020 Oct; 23(10):1102-1110. PubMed ID: 32619388
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020.
    Jensen KJ; Jensen CB; Wennerström C; Burisch J; Petersen J
    Scand J Gastroenterol; 2023 Jul; 58(7):726-736. PubMed ID: 36802972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acceptance of COVID-19 Vaccines among Patients with Inflammatory Bowel Disease in Japan.
    Nishida Y; Hosomi S; Kobayashi Y; Nakata R; Ominami M; Nadatani Y; Fukunaga S; Otani K; Tanaka F; Nagami Y; Taira K; Kamata N; Fujiwara Y
    Healthcare (Basel); 2021 Dec; 10(1):. PubMed ID: 35052170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.